Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2021-08-19 Interim / Quarterly Rep…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the period January 1, 2021 – June 30, 2021' for Oasmia Pharmaceutical AB. It contains detailed financial statements (consolidated net sales, operating profit/loss, net profit/loss, and earnings per share) for both the second quarter and the six-month period. It also includes a CEO review, strategy for growth, and technology platform descriptions. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2021
2021-08-19 English
Report from Annual General Meeting in Oasmia Pharmaceutical AB
AGM Information Classification · 99% confidence The document is explicitly titled "Report from Annual General Meeting in Oasmia Pharmaceutical AB" and details the resolutions passed during the meeting held on May 27, 2021, covering the adoption of financial statements, dividend decisions, board elections, auditor appointments, fee structures, and authorization for share issues. This content directly corresponds to the definition of AGM Information. Although it mentions an attachment, the primary content provided is the summary of the meeting results, making AGM-R the most appropriate classification over RPA or RNS.
2021-05-27 English
Kommuniké från årsstämma i Oasmia Pharmaceutical AB
AGM Information Classification · 99% confidence The document is explicitly titled 'Kommuniké från årsstämma i Oasmia Pharmaceutical AB' (Communication from the Annual General Meeting in Oasmia Pharmaceutical AB). It details the resolutions passed at the AGM held on May 27, 2021, covering the approval of financial statements, dividend decisions, election of the board and auditor, approval of remuneration reports, and authorization for share issuance. These contents are characteristic of the official minutes or summary released following an Annual General Meeting (AGM). Therefore, the correct classification is AGM-R.
2021-05-27 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Oasmia Pharmaceutical AB covering the period from January 1 to March 31, 2021. It contains detailed financial statements (net sales, operating profit, earnings per share), management commentary, business updates, and strategic outlook. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2021
2021-05-27 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the period January 1, 2021 – March 31, 2021' and contains comprehensive financial data, including consolidated net sales, operating profit/loss, net profit/loss, and earnings per share for the specified quarter. It also includes detailed management commentary, strategic updates, and operational highlights. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements, it is classified as an Interim/Quarterly Report. Q1 2021
2021-05-27 English
Annual Report 2020
Annual Report Classification · 100% confidence The document is an 'Årsredovisning' (Annual Report) for Oasmia for the period May–December 2020. It contains a comprehensive review of the company's activities, strategic outlook, management commentary, and financial statements (as indicated by the table of contents listing 'Koncernens finansiella rapporter' and 'Noter'). It is a full-length annual report, not an announcement or a summary. H2 2020
2021-04-29 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.